4Q3T
Crystal structure of Schistosoma mansoni arginase in complex with inhibitor NOHA
4Q3T の概要
エントリーDOI | 10.2210/pdb4q3t/pdb |
関連するPDBエントリー | 4Q3P 4Q3Q 4Q3R 4Q3S 4Q3U 4Q3V 4Q40 4Q41 4Q42 |
分子名称 | Arginase, MANGANESE (II) ION, GLYCEROL, ... (5 entities in total) |
機能のキーワード | arginase-deacetylase fold, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor |
由来する生物種 | Schistosoma mansoni (Blood fluke) |
タンパク質・核酸の鎖数 | 4 |
化学式量合計 | 170822.04 |
構造登録者 | Hai, Y.,Edwards, J.E.,Van Zandt, M.C.,Hoffmann, K.F.,Christianson, D.W. (登録日: 2014-04-12, 公開日: 2014-07-16, 最終更新日: 2023-09-20) |
主引用文献 | Hai, Y.,Edwards, J.E.,Van Zandt, M.C.,Hoffmann, K.F.,Christianson, D.W. Crystal Structure of Schistosoma mansoni Arginase, a Potential Drug Target for the Treatment of Schistosomiasis. Biochemistry, 53:4671-4684, 2014 Cited by PubMed Abstract: The X-ray crystal structure of arginase from Schistosoma mansoni (SmARG) and the structures of its complexes with several amino acid inhibitors have been determined at atomic resolution. SmARG is a binuclear manganese metalloenzyme that catalyzes the hydrolysis of l-arginine to form l-ornithine and urea, and this enzyme is upregulated in all forms of the parasite that interact with the human host. Current hypotheses suggest that parasitic arginases could play a role in host immune evasion by depleting pools of substrate l-arginine that would otherwise be utilized for NO biosynthesis and NO-dependent processes in the immune response. Although the amino acid sequence of SmARG is only 42% identical with that of human arginase I, residues important for substrate binding and catalysis are strictly conserved. In general, classical amino acid inhibitors such as 2(S)-amino-6-boronohexanoic acid (ABH) tend to bind more weakly to SmARG than to human arginase I despite identical inhibitor binding modes in each enzyme active site. The identification of a patch on the enzyme surface capable of accommodating the additional Cα substitutent of an α,α-disubstituted amino acid inhibitor suggests that such inhibitors could exhibit higher affinity and biological activity. The structures of SmARG complexed with two different α,α-disubstituted derivatives of ABH are presented and provide a proof of concept for this approach in the enhancement of enzyme-inhibitor affinity. PubMed: 25007099DOI: 10.1021/bi5004519 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.142 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード